Melanoma patients see 42% lower death risk with Merck-Moderna vaccine as regulators review approval

Pharmaceutical partners Merck and Moderna announced on Thursday that a personalised mRNA vaccine significantly reduced the risk of death or recurrence in patients with advanced melanoma. The late-stage trial data showed a 42 per cent reduction in these risks compared to standard treatment alone, marking a notable advance in cancer therapy development.

The companies released the top-line results early after an oncology news site broke the embargo ahead of a scheduled presentation at the European Society of Medical Oncology conference in Madrid. The full dataset has been accepted for publication in the New England Journal of Medicine, providing detailed evidence for the treatment's efficacy.

What we know

The Phase 3 trial included 1,137 patients with stage IIB to IV melanoma that had been surgically removed before entering the study. Participants were randomised to receive either the personalised mRNA vaccine combined with Merck’s Keytruda or Keytruda alone. The vaccine, known as intismeran or mRNA-4157, uses synthetic mRNA coding for up to 34 unique mutations in a patient’s cancer cells.

Moderna CEO Stéphane Bancel stated that the results reinforce the conviction that mRNA technology can fundamentally change cancer treatment. He described the findings as a defining moment for the vision of developing medicines uniquely matched to each patient’s tumour, highlighting the potential for individualised therapies to become a new paradigm in oncology.

Defender's checklist

• Verify the source of clinical trial data before citing specific efficacy percentages in professional communications.
• Check whether regulatory approval has been granted before recommending personalised mRNA vaccines for clinical use.
• Confirm the specific stage of melanoma and prior surgical history required for eligibility in similar trials.
• Monitor official publications like the New England Journal of Medicine for full dataset validation.

The background in plain language

Personalised vaccines are designed to target unique genetic mutations found in an individual’s cancer cells. Teams usually compare the genetic sequences of tumour cells with healthy tissue to identify specific markers. The vaccine then trains the immune system to recognise and attack cells displaying those markers. This approach aims to minimise damage to healthy tissue while maximising the immune response against the cancer.

What to do and how to stay safe: Merck

• Consult oncology specialists to determine if personalised mRNA therapies are appropriate for specific cancer types.
• Review clinical trial eligibility criteria carefully, including disease stage and prior treatment history.
• Monitor regulatory agency announcements for approval status and safety guidelines before adoption.
• Verify data sources through peer-reviewed journals rather than relying on early embargo breaks.

General security guidance from the TechWire Beat newsroom. It is not confirmed advice from the organisations named in this story.

Frequently asked questions

What was the primary result of the Merck and Moderna melanoma vaccine trial?

The personalised mRNA vaccine reduced the risk of death or recurrence by 42 per cent compared to standard treatment alone.

How many patients were involved in the Phase 3 trial?

The trial included 1,137 patients with stage IIB to IV melanoma who had undergone surgical removal of their tumours.

Has the vaccine received regulatory approval for clinical use?

No, Merck and Moderna are currently engaging with regulatory authorities to seek approval for the vaccine.